Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Cancer × Topotecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 36 Lung Neoplasms 28 Small Cell Lung Carcinoma 19 Neuroblastoma 17 Carcinoma, Ovarian Epithelial 15 Neoplasms 13 Leukemia, Myeloid, Acute 11 Leukemia 11 Fallopian Tube Neoplasms 11 Brain Neoplasms 11 Uterine Cervical Neoplasms 9 Recurrence 8 Retinoblastoma 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Glioma 7 Sarcoma, Ewing 6 Sarcoma 6 Lymphoma 6 Lymphoma, Follicular 5 Endometrial Neoplasms 5 Central Nervous System Neoplasms 5 Blast Crisis 5 Unspecified Adult Solid Tumor, Protocol Specific 4 Osteosarcoma 4 Neoplasm Metastasis 4 Myelodysplastic Syndromes 4 Lymphoma, Non-Hodgkin 4 Lymphoma, Large B-Cell, Diffuse 4 Gliosarcoma 4 Glioblastoma 4

Interventions

Surveys and Questionnaires 7 Bevacizumab 5 temsirolimus 4 Standard of Care 4 Sirolimus 4 Interviews as Topic 4 Vorinostat 2 Paclitaxel 2 Magnetic Resonance Spectroscopy 2 Everolimus 2 Erlotinib Hydrochloride 2 Cetuximab 2 zaleplon 1 vistusertib 1 tilsotolimod 1 pazopanib 1 olaparib 1 liposomal doxorubicin 1 capivasertib 1 apatinib 1 Videotape Recording 1 Vemurafenib 1 Valproic Acid 1 Trastuzumab 1 Topotecan 1 Temozolomide 1 Sunitinib 1 Sorafenib 1 Rehabilitation 1 Referral and Consultation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00770731 2013-02-13

Study of Temsirolimus, Topotecan, and Bortezomib

M.D. Anderson Cancer Center

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡